The impact of post‐remission granulocyte colony‐stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/10.1002/ajh.27515

Keywords:

Abstract:

Source: